Our Science – Ho Website
Mitchell Ho, Ph.D.
| Q&A With Mitchell Ho, Ph.D. - Dr. Ho is a recipient of Ovarian Cancer Research Fund's Individual Investigator Award.|
| The NIH Antibody Interest Group (ABIG) - The monthly ABIG meetings are open to everyone interested.|
| BIOC301/302 - Biochemistry I/II - BIOC 301 and 302 are a comprehensive survey of biochemistry at the graduate level.|
| Understanding Mesothelioma By CURE Media Group - Q&A With Dr. Mitchell Ho, the recipient of the Mesothelioma Applied Research Foundation Craig Kozicki Memorial Grant|
| NCI/CCR: Novel Antibody Targets Glypican-3 in Liver Cancer - Scientists in the Ho lab generated a new human single-domain antibody, HN3, recognizes glypican-3 for liver cancer therapy. (NCI/CCR News. March 11, 2013)|
| Nature Reviews: The promise of new approaches in the management of hepatocellular carcinoma - "Mitchell Ho and colleagues investigated the potential of therapeutic antibodies for HCC." Nature Reviews Gastroenterology and Hepatology, Published online 26 March 2013|
| Nature SciBX: Glypican-3 (GPC3) - NCI patent application filed; available for licensing. Contact: Mitchell Ho, National Cancer Institute, Bethesda, Md. e-mail: email@example.com. SciBX 6(11); doi:10.1038/scibx.2013.262 Published online March 21 2013|
Dataset: Global Gene Expression Microarray for 2D and 3D Cultures of NCI-H226
- Gene expression microarray datasets from the NCI-H226 mesothelioma cell line: 2D and 3D cell cultures.
| Dr Mitchell Ho's talk at 2013 AACR Annual Meeting - Discussing Phase I studies of immune-based therapies targeting mesothelin and MUC16/CA125 (video and slides)|
This page was last updated on 5/1/2013.